460
Tfelt-Hansen P. Triptans versus other migraine medicine–secondary publication. Ugeskr Laeger.
2009;171:1485–7.
Tfelt-Hansen P, Brøsen K. Pharmacogenomics and migraine: possible implications. J Headache
Pain. 2008;9:13–8.
van Baarsen LG, Vosslamber S, Tijssen M, et al. Pharmacogenomics of interferon-beta therapy in
multiple sclerosis: baseline IFN signature determines pharmacological differences between
patients. PLoS One. 2008;3:e1927.
Vernon SD, Reeves WC. The challenge of integrating disparate high-content data: epidemiologi-
cal, clinical and laboratory data collected during an in-hospital study of chronic fatigue syn-
drome. Pharmacogenomics. 2006;7:345–54.
Vosslamber S, van Baarsen LG, Verweij CL. Pharmacogenomics of IFN-beta in multiple sclerosis:
towards a personalized medicine approach. Pharmacogenomics. 2009;10:97–108.
Wager TD, Atlas LY, Lindquist MA, et al. An fMRI-based neurologic signature of physical pain.
N Engl J Med. 2013;368:1388–7.
Walker LE, Mirza N, Yip VL, et al. Personalized medicine approaches in epilepsy. J Int Med
2015;277:218–34. doi: 10.1111/joim.12322.
Yasuda CL, Cendes F. Neuroimaging for the prediction of response to medical and surgical
treatment in epilepsy. Expert Opin Med Diagn. 2012;6:295–308.
Yoshida S, Sugawara T, Nishio T, Kaneko S. Personalized medicine for epilepsy based on the
pharmacogenomic testing. Brain Nerve. 2011;63:295–9.
12 Personalized Management of Neurological Disorders